Chicago Social Drinking Project (CSDP)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00961792 |
Recruitment Status :
Active, not recruiting
First Posted : August 19, 2009
Last Update Posted : August 14, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This study attempts to elucidate the factors that contribute to escalation and maintenance of excessive ethanol drinking in young adults by:
- Examining subjective and objective response differences to alcohol and other common substances in a sample of young, adult social drinkers with varying consumption patterns.
- Determining whether response to alcohol and other substances is predictive of future consumption patterns through longitudinal follow-up interviews.
- Examining the relationship between responses to alcohol and other substances at baseline and re-examination testing to evaluate if consumption patterns moderate this relationship.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Alcoholism | Drug: Ethanol Drug: Placebo Drug: Diphenhydramine Drug: Caffeine | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 400 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Screening |
Official Title: | Individual Differences After Consumption of Alcohol and Other Common Substances and Long-Term Follow-Up of Social Drinking, Young Adults |
Study Start Date : | March 2004 |
Estimated Primary Completion Date : | December 2022 |
Estimated Study Completion Date : | December 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: Beverage with Heavy Alcohol Dose
Beverage containing 0.8 g/kg alcohol
|
Drug: Ethanol
Beverage containing 0.8 g/kg ethanol, 0.4 g/kg ethanol
Other Names:
|
Experimental: Beverage with Low Alcohol Dose
Beverage containing 0.4 g/kg alcohol
|
Drug: Ethanol
Beverage containing 0.8 g/kg ethanol, 0.4 g/kg ethanol
Other Names:
|
Placebo Comparator: Beverage with No alcohol (Placebo)
Beverage containing 0.0 g/kg alcohol to act as placebo
|
Drug: Placebo
Beverage containing 0.0 g/kg alcohol to act as placebo |
Experimental: Beverage with Diphenhydramine
Beverage containing 1.5 standard dose of Diphenhydramine (Benadryl)
|
Drug: Diphenhydramine
Beverage containing dose equivalent to 1.5 standard doses of Diphenhydramine (Benadryl)
Other Name: Benadryl |
Experimental: Beverage with Caffeine
Beverage containing the equivalent of 1.5 times participant's average caffeine consumption
|
Drug: Caffeine
Beverage containing the equivalent of 1.5 times the participant's daily caffeine intake |
- Subjective response to alcohol and other common substances utilizing mood questionnaires in social drinking young adults [ Time Frame: Measured during 5 timepoints at each experimental session: 1) Pre-drink baseline, 2) +30 minutes, 3) +60 minutes, 4) +120 minutes, and 5) +180 minutes following the initiation of beverage consumption ]
- Substance Use Behavior Reported During Follow-Up Interviews [ Time Frame: Measured at 3, 6, 9, 12, 15, 18, 21, 24, 36, 48, and 60 months following the final experimental session ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years to 29 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age 21-29
- Weigh between 110-210 lbs
- Drink alcohol at least once weekly with weekly "binge" drinking episodes
- Available to complete in-person screening and 2, 4 hour experimental sessions at the University of Chicago
- Available by phone, mail, or Internet for follow-up interviews for at least 2 years following sessions
Exclusion Criteria:
- Current or past major medical or psychiatric disorders including alcohol and substance dependence

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00961792
United States, Illinois | |
Clinical Addictions Research Laboratory | |
Chicago, Illinois, United States, 60637 |
Principal Investigator: | Andrea C King, PhD | University of Chicago |
Publications of Results:
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | University of Chicago |
ClinicalTrials.gov Identifier: | NCT00961792 |
Other Study ID Numbers: |
12119a 5R01AA013746 ( U.S. NIH Grant/Contract ) |
First Posted: | August 19, 2009 Key Record Dates |
Last Update Posted: | August 14, 2020 |
Last Verified: | August 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Alcoholism Alcohol-Related Disorders Substance-Related Disorders Chemically-Induced Disorders Mental Disorders Diphenhydramine Promethazine Ethanol Caffeine Central Nervous System Stimulants Physiological Effects of Drugs Phosphodiesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Purinergic P1 Receptor Antagonists |
Purinergic Antagonists Purinergic Agents Neurotransmitter Agents Anti-Infective Agents, Local Anti-Infective Agents Central Nervous System Depressants Sleep Aids, Pharmaceutical Hypnotics and Sedatives Anesthetics, Local Anesthetics Sensory System Agents Peripheral Nervous System Agents Antiemetics Autonomic Agents Gastrointestinal Agents |